BioNotebook: Deals from Five Prime/GSK, Actavis/Rhythm, Apricus/Forendo; a DARPA collaboration and IPO news
This article was originally published in Scrip
Five Prime, GSK expand collaboration; Actavis gains option to buy Rhythm subsidiary; Apricus licenses fispemifene from Forendo; Inovio, MedImmune partner with DARPA money; and IPO updates from DBV, Coherus, S1 Biopharma and Tobira.
You may also be interested in...
Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.